Securities Lending Top 10 Earning Equities

DataLend presents its top 10 earnings equities for December 2, 2014. This list is built on DataLend’s universe of more than 42,000 securities on loan.

Methodology: We scan our universe of more than 42,000 securities on loan to find those securities with the most expensive financing positions in the U.S., U.K., Europe and Asia. Financing costs are determined by taking the total on-loan value of a security and multiplying it by the volume-weighted average fees to borrow that security, then converting the product of those numbers to a dollar value. We then sort the most expensive securities to finance in the securities lending market in descending order.

US

Utilization

1 GOPRO CL A 98.85%
2 AMTRUST FINANCIAL SERVICES 89.83%
3 MYRIAD GENETICS 91.20%
4 KINDER MORGAN 87.75%
5 LINDSAY 86.47%
6 BURGER KING WORLDWIDE 92.02%
7 3D SYSTEMS 88.26%
8 INVENSENSE 92.56%
9 MOBILEYE 94.24%
10 MANNKIND 93.55%

UK

Utilization

1 SAINSBURYJ 74.86%
2 MONITISE 63.09%
3 LONMIN 73.47%
4 QUINDELL 92.73%
5 ASHMORE GROUP 66.66%
6 JSCJSC VTB BANK GDR 48.44%
7 GULF KEYSTONE PETROLEUM 94.78%
8 AVANTI COMMUNICATIONS GROUP 81.94%
9 NANOCO GROUP 74.13%
10 SAGA 48.78%

Europe

Utilization

1 GEMALTO (NL) 82.08%
2 SAINSBURYJ (GB) 74.86%
3 TRANSOCEAN (CH) 87.79%
4 SUEDZUCKER MANNHEIM OCHSENFURT (DE) 80.45%
5 FIAT CHRYSLER AUTOMOBILES (IT) 61.23%
6 COMPAGNIE GENERALE GEOPHYSIQUE (FR) 63.91%
7 GEMALTO (FR) 90.10%
8 TGS NOPEC GEOPHYSICAL (NO) 81.75%
9 ALPHA BANK R (GR) 34.93%
10 NORWEGIAN AIR SHUTTLE (NO) 94.06%

Far East/Australia Pacific

Utilization

1 HANERGY TFP (HK) 83.72%
2 EVERGRANDE (HK) 86.44%
3 MIXI (JP) 81.70%
4 CELLTRION (KR) 69.41%
5 ANHUI CONCH H (HK)/td> 77.35%
6 PRADA (HK) 85.12%
7 SANRIO (JP) 85.51%
8 GREE (JP) 81.33%
9 GUNGHO ONLINE (JP) 85.53%
10 HUISHAN DAIRY 68.51%

Click here for more information about DataLend’s key features.


THE INFORMATION CONTAINED HEREIN IS PROPRIETARY TO EQUILEND; MAY NOT BE COPIED OR DISTRIBUTED WITHOUT THE EXPRESS CONSENT OF EQUILEND; SHALL NOT CONSTITUTE INVESTMENT ADVICE BY EQUILEND, OR ANY REPRESENTATIVE THEREOF; IS NOT WARRANTED TO BE ACCURATE, COMPLETE OR TIMELY; IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY; IS NOT INTENDED FOR TRADING PURPOSES; AND SHOULD NOT BE CONSTRUED AS EQUILEND MAKING FORECASTS, PROJECTING RETURNS OR RECOMMENDING ANY PARTICULAR COURSE OF ACTION. NEITHER EQUILEND NOR ANY REPRESENTATIVE THEREOF SHALL BE AN ADVISOR OR A FIDUCIARY OF A VISITOR TO THIS WEBSITE. EQUILEND IS NOT RESPONSIBLE OR LIABLE IN ANY WAY TO THE READER OR VISITOR, OR TO ANY PERSON, FIRM OR CORPORATION FOR ANY DAMAGES OR LOSSES ARISING FROM ANY USE OF THE INFORMATION CONTAINED HEREIN. IN CONSIDERING THE INFORMATION CONTAINED HEREIN, A VISITOR TO THIS WEBSITE DOES SO SOLELY IN RELIANCE ON THE VISITOR’S OWN JUDGMENT. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE.

Related Posts

Previous Post
The impact of Europe’s banking reforms; liquidity will take a big hit
Next Post
Nomura wins Insurance Risk award for innovation in collateral transformation

Related Posts

Fill out this field
Fill out this field
Please enter a valid email address.

Menu
X

Reset password

Create an account